Celladon aims to reverse the downhill spiral of cardiomyocyte damage in heart failure. Its first product is a form of gene therapy, delivered by a recombinant adeno-associated viral vector, designed to augment SERCA2a-mediated calcium transport in HF patients. The SERCA2a pathway is pivotal in controlling the heart's pumping ability, and numerous studies have correlated heart failure progression with declines in SERCA2a levels.
2223 Avenida de la Playa, Suite 300
La Jolla, CA 92037
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
